• Mashup Score: 1

    The question of revascularization in patients with heart failure (HF) and severe left ventricular (LV) systolic dysfunction is almost as old as the specialty itself. 1 The STICH (Surgical Treatment for Ischemic Heart Failure) trial did not demonstrate a survival benefit of coronary artery bypass grafting at 5 years in patients with ischemic cardiomyopathy (ICM). 2 Percutaneous coronary intervention (PCI) has not been studied in patients with severe LV dysfunction. The REVIVED-BCIS2 (Revascularization for

    Tweet Tweets with this article
    • Any benefit to revascularization in heart failure? Analysis of REVIVED-BCIS trial by @MeganPelter #revascularization #stent #HF #heartfailure https://t.co/EcbqROKiPp

  • Mashup Score: 0

    Durable left ventricular assist devices (LVADs) have demonstrated improved survival rates in patients with advanced heart failure (HF) compared with those of pharmacological therapy. 1 Sequential design improvements with each generation have led to the development of the HeartMate 3 (Abbott Laboratories, Abbott Park, Illinois) LVAD, which is a fully magnetically levitated centrifugal pump that provides frictionless, wide blood-flow passages and intrinsic pulsatility. 2 The MOMENTUM 3 (Multicenter Study

    Tweet Tweets with this article
    • Improving outcomes with #LVAD therapy! 5 year analysis of the MOMENTUM trial, summarized by our recent graduating HF fellow at Univ of Kentucky, Dr Linda Njoroge @GillKentucky @UK_HealthCare @ACCinTouch https://t.co/sdKCG0dKBX

  • Mashup Score: 2

    The Heart Walk is the American Heart Association’s premiere event for raising funds to save lives from USA’s #1 and #5 killers – heart disease and stroke.

    Tweet Tweets with this article
    • As a HF physician I have seen the devastating effects of heart disease on so many patients. But also witnessed the incredible successes of medical therapy and transplantation. Join me in supporting the #AHA Heart Walk! You can make a donation here: https://t.co/UDJh0TmoCI